Document Detail


Application of restricted sequential design in a clinical protocol.
MedLine Citation:
PMID:  7407776     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Restricted sequential design is an alternative to fixed-sample analysis as a statistical tool in clinical trials. This paper presents a specific example of the rationale which led to the choice of sequential design in a clinical protocol evaluating granulocyte transfusions in children with leukemia. The main advantage of sequential design is that fewer patients may be necessary to declare statistical significance. Its application is limited to trials where (a) the result of therapy is easily defined, (b) the result of therapy is discernible in a short time interval, and (c) one randomization is being tested, although patients may be stratified. The main disadvantage of sequential design is that if the therapies being tested are similar in efficacy, the trial may require more patients than fixed-sample analysis. This potential disadvantage may be acceptable when the concern in designing a trial is to evaluate as quickly as possible a reputedly superior therapy.
Authors:
E I Thompson
Related Documents :
11701276 - Towards an international consensus on definitions and standardised outcome measures for...
18196446 - Structured early consultation with the occupational physician reduces sickness absence ...
16178136 - Uses and limitations of randomization-based efficacy estimators.
21046386 - Arterial closure devices versus manual compression for femoral haemostasis in intervent...
12780836 - A 4-year follow-up of a randomized prospective study comparing transurethral electrovap...
10355406 - Minimally invasive mitral valve surgery: the subxiphoid approach.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  64     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:    1980 Feb-Mar
Date Detail:
Created Date:  1980-11-24     Completed Date:  1980-11-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  399-403     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Agranulocytosis / therapy*
Blood Transfusion
Child
Clinical Trials as Topic / methods*
Humans
Leukemia / complications,  therapy*
Neutropenia / complications,  therapy*
Random Allocation
Research Design
Risk
Sepsis / etiology
Statistics as Topic*
Time Factors
Grant Support
ID/Acronym/Agency:
CA-21765/CA/NCI NIH HHS; RR-00584/RR/NCRR NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sequential clinical trials in cancer research.
Next Document:  Patient heterogeneity in clinical trials.